Tech Company Inital Public Offerings
Akero Therapeutics IPO
Headquartered in Cambridge, Akero Therapeutics is now a public company.
Transaction Overview
Company Name
Announced On
6/19/2019
Transaction Type
IPO
Amount
$92,000,000
Proceeds Purpose
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, for development of our product candidate, AKR-001, including completion of our Phase 2a clinical trial and a subsequent Phase 2b clinical trial, for third-party drug substance and drug product manufacturing, as well as potential pipeline expansion and for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 10th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Akero Therapeutics (Nasdaq: AKRO) is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure and death.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Cheng
Chief Operating Officer
Jonathan Young
Chief Scientific Officer
Timothy Rolph
VP - Bus. Development
Kitty Yale
Browse more venture capital transactions:
Prev: 6/19/2019: SafeAI venture capital transaction
Next: 6/19/2019: Cleave Biosciences venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs